PP patients treated with iCombo after three months more often achieved ACR20 ( 70 % vs 38 % , P < 0.001 ) , ACR50 ( 48 % vs 13 % , P < 0.001 ) and ACR70 response ( 24 % vs 4 % , P < 0.001 ) than those treated with iMono , and had more improvement in HAQ ( median decrease 0.75 vs 0.38 , P < 0.001 ) .